Introduction
============

Sustained high-efficiency daily hemodiafiltration using a cytokine-adsorbing membrane (SHEDD-fA) is an effective modality for sepsis treatment. Here we describe the effectiveness of SHEDD-fA, which makes the best use of three principles for solute removal, in the treatment of severe sepsis.

Methods
=======

Twenty-nine septic shock patients were analyzed retrospectively. SHEDD-fA was initiated after adequate fluid resuscitation and catecholamine support. Operation conditions were QB = 150 ml/minute, QF = 1,500 ml/hour (post-dilution) and QD = 300 to 500 ml/minute using an HD machine over 8 to 12 hours daily. For the purpose of maximizing cytokine adsorption efficiency, we used a large-size (2.1 m^2^) PMMA dialyzer.

Results
=======

Decrease in blood IL-6 level
----------------------------

SHEDD-fA was performed for 3 days. The percentage of IL-6 removed from the blood was 84.4 ± 25.8% (mean ± SD; *P*\< 0.01; *n*= 25; Figure [1](#F1){ref-type="fig"}). In addition, we simultaneously assayed both inlet and outlet IL-6 and found a 21.0 ± 13.4% (*P*\< 0.01; *n*= 25) removal ratio, showing that IL-6 is effectively removed after one pass through the hemofilter. Moreover, depressed monocytic HLA-DR ratio was improved from 40.6 to 51.9% in one typical case.

![**Decrease in blood IL-6 level over 3 days (left) and the removal ratio in one pass (right)**.](cc9535-1){#F1}

Hemodynamics and PaO~2~/FiO~2~improvement
-----------------------------------------

In 22 out of the 29 septic shock patients, significant decreases in the catecholamine index/mean blood pressure were observed 3 hours after the initiation of SHEDD-fA (*P*\< 0.01). In septic ARDS patients, PaO~2~/FiO~2~was significantly improved at 1 hour (*P*\< 0.01). The improvement of the abovementioned parameters continued afterwards for 72 hours. As a result, 13 of 16 patients survived.

Conclusions
===========

We propose the use of a large-size, cytokine-adsorbing hemofilter (PMMA or AN69 based membrane) and the selection of a suitable duration modality in the treatment of severe sepsis.
